Table 4 Effect of TRA on drugs prescription in relation to guidelines (secondary outcomes)
SR | According to guidelines | Against guidelines | |||
|---|---|---|---|---|---|
Aspirin | Antihypertensive | lipid-lowering | antidiabetic | ||
Brindle 2006 [16] | All CVD risk groups: No difference: 1 study High CVD risk group: Increase: 1 study | All CVD risk groups: No difference: 1 study High CVD risk group: Increase: 1 study | No difference: 1 study | – | |
Sheridan 2008 [17] | All CVD risk groups: No difference: 1 study High CVD risk group: Increase: 1 study | All CVD risk groups: No difference: 2 studies High CVD risk group: Increase: 1 study; No difference: 1 study | All CVD risk groups: No difference: 1 study High CVD risk group: No difference: 1 study | – | |
Sheridan 2010 [18] | – | – | No difference: 1 | – | – |
Waldron 2011 [35] | – | – | – | – | – |
van Dieren 2012 [36] | – | Increase: 2 studies; No difference: 1 study | Increase: 2 studies; No difference: 1 study | No difference: 1 study | – |
Willis 2012 [19] | – | – | – | – | – |
Usher-Smith 2015 [37] | – | All CVD risk groups: No difference: 3 studies; High CVD risk group: Increase: 1 study | All CVD risk groups: No difference: MA, 4 studies (RR 1,35, 95% CI 0.96 to 1.90, I2 = 0%) High CVD risk group: Increase: MA, 3 studies (RR 1,83, 95% CI 1.13 to 2.98) | All CVD risk groups: No difference: 3 studies; High CVD risk group: No difference: 2 studies | – |
Tomasik 2017 [38] | – | – | – | – | |
Karmali 2017 [39] | Increase: MA, 3 studies (RR 2,71; 95% CI 1.24 to 5.91; I2 = 0%); No difference: 2 studies | Increase: MA, 8 studies (RR 1,51, 95% CI 1.08 to 2.11, I2 = 53%); No difference: 3 studies | Increase: MA, 11 studies (RR 1,47, 95% CI 1.15 to 1.87, I2 = 40%); No difference: 4 studies | Low CVD risk group: Reduction: 1 study | |
Collins 2017 [40] | – | – | – | – | – |